A Phase I Study of the Pan-Notch Inhibitor CB-103 for Patients with Advanced Adenoid Cystic Carcinoma and Other Tumors
- Glenn J. Hanna
- , Anastasios Stathis
- , Elena Lopez-Miranda
- , Fabricio Racca
- , Doris Quon
- , Serge Leyvraz
- , Dagmar Hess
- , Bhumsuk Keam
- , Jordi Rodon
- , Myung Ju Ahn
- , Hye Ryun Kim
- , Andreas Schneeweiss
- , Josep Maria Ribera
- , Daniel DeAngelo
- , Jose Manuel Perez Garcia
- , Javier Cortes
- , Oliver Schönborn-Kellenberger
- , Dirk Weber
- , Pavel Pisa
- , Michael Bauer
- Dana-Farber Cancer Institute
- Oncology Institute of Southern Switzerland
- Università della Svizzera italiana
- Hospital Ramon y Cajal
- Hospital Quironsalud-Barcelona
- Sarcoma Oncology Center
- Charité – Universitätsmedizin Berlin
- Cantonal Hospital St. Gallen
- Seoul National University
- University of Texas Health Science Center at Houston
- Yonsei University
- Heidelberg University
- Institute Catala Oncologia
- Pangaea Oncology
- Medica Scientia Innovation Research (MedSIR)
- Medica Scientia Innovation Research (MedSIR)
- Cogitars GmbH
- Cellestia Biotech AG
- piMedConsulting Ltd
- Cellestia Biotech AG
- Vall d’Hebron University Hospital
Research output: Contribution to journal › Article › peer-review
38
Link opens in a new tab
Scopus
citations